neoantigen SLP vaccine

The **neoantigen SLP vaccine** is a personalized cancer immunotherapy platform that utilizes synthetic long peptides (SLPs), typically 20–30 amino acids in length, to target tumor-specific neoantigens. These neoantigens arise from somatic mutations unique to an individual patient's tumor cells and are absent from normal tissue, allowing for a highly specific anti-tumor immune response with minimal risk of autoimmunity. The vaccine is manufactured on a patient-specific basis by identifying mutations through whole-exome and RNA sequencing, followed by bioinformatic prediction of high-affinity neoepitopes. When administered, often in combination with an adjuvant such as poly-ICLC (a TLR-3 agonist), the SLPs are taken up by antigen-presenting cells, processed, and presented on MHC class I and II molecules to elicit robust CD4+ and CD8+ T cell responses. This modality is currently being investigated in various clinical trials for advanced melanoma, glioblastoma, and other solid tumors.

Other names

synthetic long peptide neoantigen vaccinepersonalized neoantigen peptide vaccineSLP neoantigen vaccine